Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages
In summary, our results reveal that anti-S15×GM CSF may serve as an effective therapeutic approach for solid tumors.
Authors
- Mingjiu Chen
- Shuang Qu (ORCID: https://orcid.org/0000-0003-0324-7706)
- Xiaoyao Hao
- Jiajing Luo
- Zemeng Ma (ORCID: https://orcid.org/0000-0002-0869-0793)
- Jinyu Liu (ORCID: https://orcid.org/0000-0002-1000-9434)
- Jun Li (ORCID: https://orcid.org/0000-0003-3387-695X)
- Hongyan Li (ORCID: https://orcid.org/0000-0002-7073-5198)
- Wenwen Dai (ORCID: https://orcid.org/0000-0001-6533-9513)
- Dihan Zhu
- Quanli Zhang (ORCID: https://orcid.org/0000-0003-3541-4812)
- Shouyong Gu
Institutions
- China Pharmaceutical University (CN)
- Jiangsu Second Normal University (CN)
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-010580
- Citations
- 4
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 3.22